

Andrew W Roberts

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5908906/andrew-w-roberts-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231
papers

19,925
citations

68
h-index

139
g-index

238
ext. papers

22,925
ext. citations

7.8
avg, IF

6.35
L-index

#	Paper	IF	Citations
231	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013 , 19, 202-8	50.5	1922
230	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 311-22	59.2	1164
229	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006 , 10, 389-99	24.3	1049
228	Programmed anuclear cell death delimits platelet life span. <i>Cell</i> , 2007 , 128, 1173-86	56.2	763
227	SOCS3 negatively regulates IL-6 signaling in vivo. <i>Nature Immunology</i> , 2003 , 4, 540-5	19.1	663
226	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>Journal of Clinical Oncology</i> , 2012 , 30, 488-96	2.2	622
225	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature</i> , 2016 , 538, 477-483	30.4	617
224	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 768-778	21.7	536
223	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 242-52	36.3	474
222	Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. <i>Immunity</i> , 1999 , 10, 183-96	32.3	474
221	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 826-833	2.2	442
220	RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. <i>Cell</i> , 2014 , 157, 1175-88	56.2	400
219	Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 1195-200	11.5	303
218	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 14907-12	11.5	291
217	Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1788-93	2.2	278
216	Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 9324-9	11.5	266
215	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. <i>Blood</i> , 2009 , 114, 663-6	2.2	240

214	G-CSF: a key regulator of neutrophil production, but that's not all!. <i>Growth Factors</i> , 2005 , 23, 33-41	1.6	239
213	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1211-1223	59.2	226
212	SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. <i>Immunity</i> , 2004 , 20, 153-65	32.3	223
211	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , 2017 , 18, 230-240	21.7	221
210	Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. <i>Blood</i> , 2011 , 118, 1663-74	2.2	199
209	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018 , 8, 1582-1597	24.4	194
208	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019 , 9, 342-353	24.4	188
207	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017 , 130, 2392-2400	2.2	182
206	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016 , 127, 3215-24	2.2	181
205	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1973-1980	2.2	174
204	Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5614-8	11.5	169
203	Suppressor screen in Mpl ^{-/-} mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 6553-8	11.5	162
202	SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1571-81	15.9	162
201	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. <i>Cancer Cell</i> , 2018 , 34, 879-891	24.3	161
200	Targeting GM-CSF in inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 37-48	8.1	160
199	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019 , 134, 851-859	2.2	151
198	Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. <i>Blood</i> , 2012 , 119, 5807-16	2.2	150
197	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2017-31	16.6	139

196	Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 500-10		138
195	Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. <i>Science</i> , 2000 , 288, 2219-2233	33.3	136
194	Genetic Influences Determining Progenitor Cell Mobilization and Leukocytosis Induced by Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997 , 89, 2736-2744	2.2	131
193	A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. <i>Blood</i> , 2008 , 112, 5193-201	2.2	126
192	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 17961-6	11.5	124
191	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. <i>Blood</i> , 2017 , 129, 3362-3370	2.2	114
190	Targeting BCL2 for the treatment of lymphoid malignancies. <i>Seminars in Hematology</i> , 2014 , 51, 219-27	4	112
189	Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. <i>Leukemia</i> , 2014 , 28, 2213-21	10.7	106
188	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. <i>Blood</i> , 2016 , 128, 1834-1844	2.2	105
187	The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes. <i>Journal of Immunology</i> , 2002 , 168, 3376-86	5.3	103
186	The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. <i>Molecular Pharmacology</i> , 2010 , 77, 483-94	4.3	102
185	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood</i> , 2016 , 128, 1382-95	2.2	100
184	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1 β . <i>Journal of Experimental Medicine</i> , 2015 , 212, 927-38	16.6	97
183	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. <i>Leukemia</i> , 2018 , 32, 303-317	10.7	96
182	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019 , 134, 111-122	2.2	94
181	Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 11398-403	11.5	94
180	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019 , 25, 119-129	50.5	94
179	A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1406-15	1.9	90

178	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018 , 24, 4371-4379	12.9	90
177	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. <i>Blood</i> , 2015 , 125, 2649-55	2.2	89
176	Mouse loci for malaria-induced mortality and the control of parasitaemia. <i>Nature Genetics</i> , 1997 , 17, 380-383	36.3	89
175	Targeting BCL-2-like Proteins to Kill Cancer Cells. <i>Trends in Cancer</i> , 2016 , 2, 443-460	12.5	88
174	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019 , 10, 2385	17.4	84
173	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009 , 23, 2034-41	10.7	84
172	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 905-917	10.7	84
171	Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 13135-13140	11.5	79
170	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015 , 126, 832-837	2.2	79
169	GFI1B mutation causes a bleeding disorder with abnormal platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 2039-47	15.4	76
168	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 89-98	6.1	74
167	Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. <i>PLoS Pathogens</i> , 2010 , 6, e1001236	7.6	74
166	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015 , 170, 669-78	4.5	69
165	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. <i>Leukemia</i> , 2014 , 28, 1207-15	10.7	69
164	The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. <i>Blood</i> , 2005 , 105, 3512-20	2.2	68
163	Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 16442-7	11.5	66
162	Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. <i>Blood</i> , 2012 , 119, 5850-8	2.2	63
161	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010 , 150, 39-45	4.5	62

160	Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. <i>Stem Cells</i> , 1995 , 13, 512-6	5.8	62
159	Cytokine Production and Function in c-mpl ^D Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production. <i>Blood</i> , 1998 , 91, 2745-2752	2.2	60
158	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019 , 9, 354-369	24.4	60
157	The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. <i>Annals of Hematology</i> , 2007 , 86, 101-5	3	59
156	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 254-254	2.2	58
155	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020 , 44, 100672	11.1	57
154	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. <i>Blood</i> , 2018 , 132, 1526-1534	2.2	57
153	Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. <i>Blood</i> , 2007 , 109, 2380-8	2.2	57
152	Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. <i>EMBO Reports</i> , 2010 , 11, 640-6	6.5	55
151	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020 , 135, 773-777	2.2	55
150	The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. <i>Blood</i> , 2007 , 110, 1466-74	2.2	52
149	Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responses. <i>Immunology and Cell Biology</i> , 2002 , 80, 231-40	5	48
148	The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34(+) stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. <i>Cellular and Molecular Immunology</i> , 2012 , 9, 446-54	15.4	46
147	Acute left ventricular failure following melphalan and fludarabine conditioning. <i>Bone Marrow Transplantation</i> , 2001 , 28, 101-3	4.4	46
146	Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). <i>Blood</i> , 2009 , 113, 4819-20	2.2	45
145	Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. <i>Stem Cells</i> , 2006 , 24, 604-14	5.8	45
144	A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2005 , 11, 5504-14	12.9	45
143	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 4527-4533	12.9	43

142	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3506-3517	2.2	43
141	Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 16333-8	11.5	42
140	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. <i>Internal Medicine Journal</i> , 2004 , 34, 192-200	1.6	41
139	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R β / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. <i>Blood</i> , 2014 , 124, 120-120	2.3	40
138	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	39
137	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 2599-604	11.5	37
136	Neutrophils require SHP1 to regulate IL-1 β production and prevent inflammatory skin disease. <i>Journal of Immunology</i> , 2011 , 186, 1131-9	5.3	36
135	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. <i>Cell Death and Disease</i> , 2012 , 3, e409	9.8	36
134	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1035-1038	10.7	35
133	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020 , 135, 2266-2270	2.2	35
132	IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. <i>Immunology and Cell Biology</i> , 2012 , 90, 124-9	5	34
131	SOCS3 regulates graft-versus-host disease. <i>Blood</i> , 2010 , 116, 287-96	2.2	34
130	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. <i>Pathology</i> , 2011 , 43, 525-35	1.6	33
129	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015 , 126, 830-830	2.2	33
128	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , 2020 , 136, 2027-2037	2.2	33
127	Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 603-7	4.7	32
126	Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. <i>Stem Cells</i> , 1996 , 14 Suppl 1, 124-32	5.8	30
125	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 108-108	2.2	30

124	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007 , 40, 157-63	4.4	28
123	Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites. <i>Journal of Cell Biology</i> , 2002 , 158, 115-25	7.3	28
122	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014 , 124, 325-325	2.2	28
121	Immune thrombocytopenia complicating pulmonary tuberculosis: case report and investigation of mechanisms. <i>Thorax</i> , 1992 , 47, 396-7	7.3	27
120	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. <i>Haematologica</i> , 2020 , 105, e76-e79	6.6	26
119	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, e188-e191	4.5	24
118	Fas regulates neutrophil lifespan during viral and bacterial infection. <i>Journal of Leukocyte Biology</i> , 2015 , 97, 321-6	6.5	24
117	Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 16625-30	11.5	24
116	Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. <i>Clinical Cancer Research</i> , 2009 , 15, 714-22	12.9	24
115	Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. <i>Experimental Hematology</i> , 2002 , 30, 1248-56	3.1	23
114	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. <i>Leukemia</i> , 2016 , 30, 1531-41	10.7	22
113	A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 560-7	4.7	22
112	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. <i>Blood</i> , 2013 , 122, 1789-1789	2.2	22
111	Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. <i>Experimental Hematology</i> , 2008 , 36, 786-98	3.1	21
110	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. <i>Blood</i> , 2006 , 108, 58-58	2.2	20
109	Current challenges and novel treatment strategies in double hit lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 52-64	5.7	19
108	Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). <i>Blood</i> , 2013 , 121, 1479-81	2.2	19
107	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2006 , 37, 923-8	4.4	19

106	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004 , 34, 447-53	4.4	19
105	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 435-442	4.7	19
104	Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells. <i>PLoS ONE</i> , 2016 , 11, e0162111	3.7	19
103	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020 , 27, 2217-2233	12.7	18
102	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 975-975	2.2	18
101	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012 , 120, 304-304	2.2	17
100	Therapeutic development and current uses of BCL-2 inhibition. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 1-9	3.1	17
99	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020 , 4, 165-173	7.8	17
98	Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. <i>Growth Factors</i> , 2009 , 27, 384-93	1.6	16
97	Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice. <i>Leukemia</i> , 2000 , 14, 657-61	10.7	16
96	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. <i>Nature Immunology</i> , 2020 , 21, 54-64	19.1	16
95	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016 , 43, 274-9	5.5	15
94	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019 , 134, 756-756	2.2	15
93	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015 , 126, 3038-3038	3.2	15
92	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. <i>Blood Advances</i> , 2020 , 4, 2762-2767	7.8	14
91	Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. <i>Leukemia and Lymphoma</i> , 2002 , 43, 437-9	1.9	14
90	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2011 , 118, 282-282	2.2	14
89	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. <i>Blood</i> , 2021 , 137, 2721-2735	2.2	14

88	Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015 , 45, 371-82	1.6	13
87	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017 , 47, 938-951	1.6	13
86	Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1448-50	1.9	13
85	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. <i>Pathology</i> , 2006 , 38, 336-42 ^{1.6}	1.6	13
84	Venetoclax: a primer. <i>Blood Advances</i> , 2017 , 1, 467	7.8	12
83	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1678-1685	2.2	12
82	Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. <i>Cancer Cell</i> , 2019 , 36, 341-343	24.3	12
81	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. <i>Bone Marrow Transplantation</i> , 2008 , 41, 651-8	4.4	12
80	Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha. <i>Growth Factors</i> , 2007 , 25, 319-28	1.6	12
79	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019 , 134, 170-170	2.2	12
78	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. <i>Oncogene</i> , 2020 , 39, 2009-2023	9.2	12
77	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800359	2.2	12
76	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). <i>Blood</i> , 2018 , 132, 333-333	2.2	11
75	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015 , 126, LBA-6-LBA-6	2.2	11
74	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 3230-3230	2.2	11
73	Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. <i>Transplantation</i> , 2015 , 99, 128-32	1.8	10
72	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015 , 45, 94-105	1.6	10
71	Mini-allografts for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1999 , 29, 308-14		10

70	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3849-3849	2.2	10
69	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 2939-2939	2.2	10
68	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. <i>Genome Biology</i> , 2021 , 22, 310	18.3	10
67	Comprehensive characterization of single cell full-length isoforms in human and mouse with long-read sequencing		10
66	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. <i>Blood</i> , 2006 , 107, 1733-5; author reply 1735	2.2	9
65	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021 , 5, 4054-4058	7.8	9
64	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2014 , 1, e112-9	14.6	8
63	Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. <i>Molecular Immunology</i> , 2008 , 45, 2888-96	4.3	8
62	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 30, 645-50	4.4	8
61	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. <i>Blood</i> , 2013 , 122, 1304-1304	2.2	8
60	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016 , 46, 737-41	1.6	8
59	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017 , 47, 35-49	1.6	7
58	A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e53-e54	2	7
57	Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. <i>British Journal of Haematology</i> , 2002 , 119, 204-11	4.5	7
56	Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2003 , 25, 119-25		7
55	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2012 , 120, 178-178	2.2	7
54	BCL2 and MCL1 inhibitors for hematologic malignancies. <i>Blood</i> , 2021 , 138, 1120-1136	2.2	7
53	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. <i>Internal Medicine Journal</i> , 2004 , 34, 431-4	1.6	6

52	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.. <i>Blood</i> , 2004 , 104, 2253-2253	2.2	6
51	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 4395-4395	2.2	6
50	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , 2021 ,	7.8	6
49	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020 , 4, 4849-4859	7.8	6
48	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021 , 138, 836-846	2.2	6
47	Towards a four-dimensional view of neutrophils. <i>Methods in Molecular Biology</i> , 2012 , 844, 87-99	1.4	5
46	Bortezomib: putting mantle cell lymphoma on death row. <i>Leukemia and Lymphoma</i> , 2008 , 49, 657-8	1.9	5
45	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018 , 132, 183-183	2.2	5
44	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 7-8	2.2	5
43	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. <i>Blood</i> , 2013 , 122, 537-537	2.2	5
42	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015 , 21, 5222-34	12.9	4
41	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015 , 45, 335-43	1.6	4
40	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. <i>Cancer Discovery</i> , 2019 , 9, 998-1000	24.4	4
39	BH3-mimetics--the solution to chemoresistance?. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1069-72	1.9	4
38	Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1994 , 24, 541-6		4
37	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 2033-2033	2.2	4
36	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021 , 27, 4690-4695	12.9	4
35	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018 , 48, 786-794	1.6	3

34	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, LBA-7-LBA-7	2.2	3
33	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019 , 134, 462-462	2.2	3
32	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012 , 120, 3923-3923	2.2	3
31	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021 , 2, 266-271	0.9	3
30	Germline loss-of-function variants in the base-excision repair gene MBD4 cause a Mendelian recessive syndrome of adenomatous colorectal polyposis and acute myeloid leukaemia		3
29	Donald Metcalf (1929-2014). <i>Cell</i> , 2015 , 160, 361-2	56.2	2
28	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 909-11	1.9	2
27	Abnormal neutrophil phenotype and neutrophil FcR3 deficiency corrected by bone marrow transplantation. <i>Transfusion</i> , 1995 , 35, 874-8	2.9	2
26	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 9-10	2.2	2
25	Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. <i>Blood</i> , 2010 , 116, 3943-3943	2.2	2
24	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , 2019 , 134, 3999-3999	2.2	2
23	BCL2 inhibition in double hit lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1928-9	1.9	1
22	The diagnosis of abdominal aortic aneurysms. <i>ANZ Journal of Surgery</i> , 1974 , 44, 360-2	1	1
21	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). <i>Blood</i> , 2020 , 136, 16-16	2.2	1
20	Targeting apoptotic pathways to treat lymphoid malignancies. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2016 , 57, 2054-2058	1.8	1
19	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 15-16	2.2	0
18	Venetoclax for the treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 2019 , 3, 4-4	1.8	0
17	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). <i>Leukemia and Lymphoma</i> , 2021 , 62, 2981-2991	1.9	0

- 16 Reply to M. Cavo. *Journal of Clinical Oncology*, **2009**, 27, e188-e188 2.2
- 15 Optimal regimens for the mobilization and collection of peripheral blood progenitor cells from normal donors. *Leukemia and Lymphoma*, **1997**, 27, 77-82 1.9
- 14 All-trans retinoic acid-chemotherapy interactions in acute promyelocytic leukaemia. *Australian and New Zealand Journal of Medicine*, **1992**, 22, 704
- 13 Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. *Blood*, **2004**, 104, 2262-2262 2.2
- 12 Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. *Blood*, **2005**, 106, 1970-1970 2.2
- 11 A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.. *Blood*, **2005**, 106, 5162-5162 2.2
- 10 Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. *Blood*, **2007**, 110, 5115-5115 2.2
- 9 Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. *Blood*, **2014**, 124, 2103-2103 2.2
- 8 Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1. *Journal of Cell Biology*, **2015**, 209, 2095OIA104 7.3
- 7 Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. *Blood*, **2016**, 128, 338-338 2.2
- 6 Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. *Blood*, **2008**, 112, 2188-2188 2.2
- 5 Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. *Journal of Cell Biology*, **2011**, 194, i12-i12 7.3
- 4 Necroptotic Death Of RIPK1-Deficient HSC Compromises Hematopoiesis. *Blood*, **2013**, 122, 218-218 2.2
- 3 Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. *Blood*, **2013**, 122, 2143-2143 2.2
- 2 Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies. *Blood*, **2021**, 138, 1089 2.2
- 1 BCL2 Inhibitors: Insights into Resistance. *Resistance To Targeted Anti-cancer Therapeutics*, **2018**, 23-43 0.3